Researchers at McMaster University are developing two rapid diagnostic technologies that could make personalised mental health treatments more accessible by dramatically reducing the time needed to monitor medication levels.
The team is working on a handheld finger-prick blood test and a wearable device using microneedle technology, both designed to measure concentrations of psychiatric medications in the body. The aim is to deliver laboratory-level accuracy in around 10 minutes, rather than the up to 15 days currently required for results from specialist laboratories.
Backed by $1.2m in funding from the Natural Sciences and Engineering Research Council of Canada (NSERC), the project could give clinicians the information needed to adjust medication doses during a single appointment, helping patients avoid ineffective treatment and potentially harmful side effects.
Reducing the risks of psychiatric medication
Finding the right dose of medication for mental health conditions can be complicated. Psychotropic drugs must be prescribed carefully because the difference between an effective dose and one that causes toxicity can be extremely small.
Individual responses also vary considerably. Factors including age, genetics, metabolism, diet and other medications can influence how a drug behaves in the body, meaning a dosage that works for one patient may be unsuitable for another.
Clinicians increasingly rely on therapeutic drug monitoring (TDM) to address this challenge. The laboratory technique measures the concentration of a medication in a patient’s bloodstream, allowing prescribers to make more informed decisions about dosage.
However, the process is often slow, with results from specialist laboratories taking up to 15 days to arrive. This can leave patients experiencing prolonged periods of ineffective treatment or unwanted side effects while clinicians wait for the information needed to make adjustments.
Two technologies designed for faster results
Led by Leyla Soleymani, who spearheads engineering innovation for NexusHealth at McMaster University, the research team wants to bring therapeutic drug monitoring directly into clinical settings.
The proposed finger-prick test and wearable sensor are being developed to provide rapid measurements without requiring samples to be sent away for conventional laboratory analysis.
Both technologies will use aptamers, which are short strands of DNA engineered to recognise particular molecules. Integrated into electronic chips, these biological sensors will detect specific psychiatric drugs in either blood or interstitial fluid beneath the skin.
When a target drug is detected, the chip generates an electrical signal. This information is then transmitted to a nearby smartphone, allowing clinicians to access results almost immediately.
The combination of DNA-based sensing and electronic detection is intended to deliver the accuracy of laboratory testing within the timeframe of a routine medical appointment.
Patient involvement shapes device development
The design of the technologies has also been influenced by direct consultations with patients, families and healthcare professionals.
Initially, Soleymani’s team considered developing a device for continuous, minute-by-minute monitoring at home. However, discussions with those who would ultimately use the technology revealed that this approach did not reflect their needs.
The researchers subsequently changed direction, with input coordinated through the Research Institute at St. Joseph’s Health System.
These consultations helped determine practical considerations, including where the devices would be used and how frequently patients would need monitoring. Those decisions influenced both the physical design of the technologies and the chemistry used in their development.
The project brings together expertise from McMaster University and the University of Waterloo. Researchers Mahla Poudineh and Juewen Liu are contributing specialist knowledge in wearable biosensing, microneedle technologies and DNA aptamers.
Their previous collaboration on aptamer-based biosensors, including diagnostics for lactate monitoring, provides a foundation for developing the new devices.
Preparing for clinical validation
The research team is also working with LifeLasb, whose laboratory infrastructure and expertise will support the validation and development work required before the technologies can enter clinical practice.
The partnership is intended to help establish the reliability of the diagnostics and address the challenges involved in translating the research into practical healthcare applications.
The researchers anticipate that prototypes could be ready for clinical validation within four years.
If successful, the technologies could significantly shorten the time between identifying a medication-related problem and adjusting treatment, giving clinicians a more immediate way to respond to individual patients’ needs.
For personalised mental health treatments, reducing the wait for reliable drug-monitoring results could represent an important step towards more responsive and individually tailored care.